Ohara Pharmaceutical Co., Ltd.

Ohara Pharmaceutical is a Japanese pharmaceutical company focused on the development, manufacturing, and distribution of both generic and innovative drugs. The company has achieved marketing authorization for several products including recombinant enzymes and monoclonal antibodies for oncology and rare disease indications. Notable approvals include Glucarpidase (“Megludase®”) for methotrexate toxicity and Unituxin® for neuroblastoma. The pipeline includes small molecules, enzymes, and mAbs targeting cancer, metabolic disorders, infectious diseases, and neurological conditions. Recent clinical activity includes expansion into dialysis services in Africa.